160. 先天性魚鱗癬 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 42 / 薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
00305800
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
1643368-58-4
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
ADX-102 Topical Dermal Cream (reproxalap)
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States;
Active topical NS2 dermatologic cream
Aldeyra Therapeutics, Inc.
2015 Phase 2 NCT02402309 United States;
Adalimumab
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT02113904 France;
Apply VEREGEN ® on a randomized area and the moisturizing cream of the other side
Centre Hospitalier Universitaire de Nice
2010 Phase 3 NCT01222000 France;
Atorvastatin
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 Japan;
BMS-931699
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS-986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BPR277
Novartis Pharma Services AG
2013 - EUCTR2011-000917-38-NL France;Germany;Netherlands;United States;
2011 - EUCTR2011-000917-38-DE France;Germany;Netherlands;United States;
BPR277 ointment (controlled application)
Novartis Pharmaceuticals
2011 Phase 1 NCT01428297 France;Germany;Netherlands;United States;
BTK Inhibitor
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
CNT-02
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
2016 - NCT02830763 Italy;Japan;
Cholesterol
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 Japan;
Dupilumab Injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation;
Dupilumab Prefilled Syringe
University Hospital, Toulouse
2020 Phase 2/Phase 3 NCT04244006 France;
Dupixent
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France;
Epithelial sheet generated from transduced autologous keratinocytes using pCCL-INVO-SP
GOSH/ICH Joint Research & Development Office
2013 Phase 1 EUCTR2011-003212-22-GB United Kingdom;
Fibrate treatment
Maastricht University Medical Center
2011 Phase 4 NCT01527318 Netherlands;
Glucose
University Hospital, Toulouse
2015 - NCT02383316 France;
Hematopoetic Stem Cell Transplantation
University of Pittsburgh
2012 - NCT03333200 United States;
Humira
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France;
Isotretinoin
Timber Pharmceuticals LLC
2019 Phase 2 NCT04154293 Australia;United States;
KB105
Krystal Biotech, Inc.
2019 Phase 1/Phase 2 NCT04047732 United States;
L04AB04
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France;
Lipoxygenase inhibitor
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands;
Lovastatin
Northwestern University
2011 Phase 2 NCT01110642 United States;
Monolaurin cream
Cellegy Pharmaceuticals
1996 Phase 3 NCT00004690 -
None
Orencia
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
Oxiconazole
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 Japan;
PAT-001,
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States;
Pimecrolimus Cream
Children's Hospital of Philadelphia
2005 Phase 1/Phase 2 NCT00208026 United States;
RVG 18388
SAR231893
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France;
SXR1096
Sixera Pharma
2022 Phase 1;Phase 2 EUCTR2021-003210-39-AT Austria;Finland;
2021 Phase 1;Phase 2 EUCTR2021-003210-39-FI Finland;
Secukinumab
Northwestern University
2016 Phase 2 NCT03041038 United States;
Secukinumab Injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation;
Simvastatin
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000037278 China;
Ustekinumab Injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation;
VEREGEN(R)
Nice University Hospital
2009 - EUCTR2009-013656-77-FR France;
Vehicle
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States;
Vehicle of ADX-102 Topical Dermal Cream
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States;
Zyflo CR
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands;
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
1643368-58-4
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
ADX-102 Topical Dermal Cream (reproxalap)
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States;
Active topical NS2 dermatologic cream
Aldeyra Therapeutics, Inc.
2015 Phase 2 NCT02402309 United States;
Adalimumab
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT02113904 France;
Apply VEREGEN ® on a randomized area and the moisturizing cream of the other side
Centre Hospitalier Universitaire de Nice
2010 Phase 3 NCT01222000 France;
Atorvastatin
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 Japan;
BMS-931699
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS-986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BPR277
Novartis Pharma Services AG
2013 - EUCTR2011-000917-38-NL France;Germany;Netherlands;United States;
2011 - EUCTR2011-000917-38-DE France;Germany;Netherlands;United States;
BPR277 ointment (controlled application)
Novartis Pharmaceuticals
2011 Phase 1 NCT01428297 France;Germany;Netherlands;United States;
BTK Inhibitor
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
CNT-02
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
2016 - NCT02830763 Italy;Japan;
Cholesterol
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 Japan;
Dupilumab Injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation;
Dupilumab Prefilled Syringe
University Hospital, Toulouse
2020 Phase 2/Phase 3 NCT04244006 France;
Dupixent
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France;
Epithelial sheet generated from transduced autologous keratinocytes using pCCL-INVO-SP
GOSH/ICH Joint Research & Development Office
2013 Phase 1 EUCTR2011-003212-22-GB United Kingdom;
Fibrate treatment
Maastricht University Medical Center
2011 Phase 4 NCT01527318 Netherlands;
Glucose
University Hospital, Toulouse
2015 - NCT02383316 France;
Hematopoetic Stem Cell Transplantation
University of Pittsburgh
2012 - NCT03333200 United States;
Humira
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France;
Isotretinoin
Timber Pharmceuticals LLC
2019 Phase 2 NCT04154293 Australia;United States;
KB105
Krystal Biotech, Inc.
2019 Phase 1/Phase 2 NCT04047732 United States;
L04AB04
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France;
Lipoxygenase inhibitor
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands;
Lovastatin
Northwestern University
2011 Phase 2 NCT01110642 United States;
Monolaurin cream
Cellegy Pharmaceuticals
1996 Phase 3 NCT00004690 -
None
Orencia
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
Oxiconazole
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 Japan;
PAT-001,
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States;
Pimecrolimus Cream
Children's Hospital of Philadelphia
2005 Phase 1/Phase 2 NCT00208026 United States;
RVG 18388
SAR231893
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France;
SXR1096
Sixera Pharma
2022 Phase 1;Phase 2 EUCTR2021-003210-39-AT Austria;Finland;
2021 Phase 1;Phase 2 EUCTR2021-003210-39-FI Finland;
Secukinumab
Northwestern University
2016 Phase 2 NCT03041038 United States;
Secukinumab Injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation;
Simvastatin
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000037278 China;
Ustekinumab Injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation;
VEREGEN(R)
Nice University Hospital
2009 - EUCTR2009-013656-77-FR France;
Vehicle
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States;
Vehicle of ADX-102 Topical Dermal Cream
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States;
Zyflo CR
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands;